OR WAIT null SECS
Symbiosis Pharmaceutical Services has successfully completed an on-site inspection, performed by the MHRA, of its expanded facility in Stirling, UK.
Contract manufacturing organization (CMO), Symbiosis Pharmaceutical Services, has successfully completed an on-site inspection, performed by the Medicines and Healthcare products Regulatory Authority (MHRA), of its expanded facility in Stirling, United Kingdom.
According to a Sep. 15, 2021 press release, the company, which specializes in the sterile manufacture of vaccines, pharmaceuticals, and biopharmaceuticals, had been undertaking a phased expansion to its manufacturing support capability at its Stirling site. As part of the commission of the expansion, the MHRA performed an on-site inspection and provided positive feedback on the new storage and warehousing capabilities, which will now be added to the existing good manufacturing practice (GMP) licenses held by the company.
“For the past year we have focused on upgrading our existing world class facilities, in terms of capability and scale, in preparation for continued business growth” said Colin MacKay, CEO of Symbiosis, in the press release. “This new expansion phase is the latest effort in what has been a sustained investment in both the people and the organic growth of the business over the last 10 years.”
“By expanding our warehousing and storage facilities we are better placed to meet the increasingly varied demands of both established and emerging markets, such as cell and gene therapies. Our ability to handle the technical complexity of these products as well as the growth we have seen in this specialist market underpins our continued investment not only in infrastructure but in our regulatory and technical strength,” MacKay continued, in the press release. “We are proud to have successfully completed the expansion of our warehouse and storage facilities—both on time and on budget—and that the MHRA has inspected and granted us extended license to use without any concern.”